培美曲塞联合顺铂在肺腺癌患者中的临床治疗效果及对甲状腺转录因子-1和神经元特异性烯醇化酶水平的影响

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (0 KB) HTML (35 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the clinical effect of Pemetrexed combined with Cisplatin in patients with lung adenocarcinoma and its effect on the levels of thyroid transcription factor-1(TTF-1)and neuron-specific enolase(NSE).Methods Seventy-eight patients with lung adenocarcinoma treated in Loudi Central Hospital from September 2017 to December 2019 were selected as research subjects,and were retrospectively analyzed.According to different treatment methods,patients were divided into control group(n=39)and study group(n=39).The Docetaxel combined with Cisplatin was given to the control group,and the Pemetrexed combined with Cisplatin was given to the research group.The objective response rate(ORR)and the disease control rate(DCR)in the two groups were observed.The occurrence of adverse reactions was compared between the two groups.The levels of tumor markers(serum TTF-1 and serum NSE)were compared between the two groups.Results The ORR and DCR in the research group were higher than those in the control group,with statistically significant differences(P＜0.05).The incidence rates of adverse reactions in the research group were lower than those in the control group,with statistically significant differences(P＜0.05).The serum TTF-1 and serum NSE levels after treatment in the research group were lower than those in the control group,with statistically significant differences(P ＜0.05).Conclusion In patients with lung adenocarcinoma,the combined use of Pemetrexed and Cisplatin can improve the efficacy,with fewer adverse reactions,and can also reduce the levels of serum TTF-1 and serum NSE.

Key words： Tumor markers Lung adenocarcinoma Serum thyroid transcription factor-1 Serum neuron-specific enolase Pemetrexed Cisplatin

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WU Hua

Cite this article:

WU Hua. Clinical effect of Pemetrexed combined with Cisplatin in patients with lung adenocarcinoma and its effect on the levels of thyroid transcription factor-1 and neuron-specific enolase[J]. 中国当代医药, 2021, 28(26): 137-140.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I26/137

[1]	周毅，周健，张莹，等.培美曲塞联合奈达铂治疗晚期肺腺癌临床疗效及其安全性观察[J].第三军医大学学报，2018，40（13）：1236-1241.
[2]	Xiao JW，Miao K，Yan L，et al.Randomized controlled trial of endostar combined with cisplatin/pemetrexed chemo-therapy for elderly patients with advanced malignant pleural effusion of lung adenocarcinoma[J].J Buon，2018，23（1）：92-97.
[3]	张宁，李凌云，刘宏杰.培美曲塞与铂类化疗药联合使用对晚期肺腺癌患者的效果观察[J].贵州医药，2019，43（3）：415-417.
[5]	李梅，耿一超，杨文刚，等.培美曲塞+顺铂或多西他赛＋顺铂同期胸部IMRT 治疗Ⅳ期肺腺癌的疗效和安全性[J].中华放射肿瘤学杂志，2018，27（6）：564-569.
[6]	刘秋华，林榕波.实体瘤疗效评价标准（RECIST）指南1.1 版[C]//第十二届全国临床肿瘤大会暨2009年CSCO 学术年会，2009.
[7]	刘树勋，赵嗣钰，江辉斌，等.特罗凯靶向治疗联合培美曲塞和顺铂治疗非小细胞肺癌的临床研究[J].中国医师杂志，2019，21（8）：1229-1231.
[4]	Chen WQ，Li P，Wang Q，et al.A randomized controlled study of erlotinib versus pemetrexed combined with cisplatin in neoadjuvant therapy of stage ⅢA EGFR-mutant lung adenocarcinoma[J].Zhonghua Zhong Liu Za Zhi，2018，40（2）：133-137.
[8]	Nishio M，Kim DW，Wu YL，et al.Crizotinib Versus Chemotherapy in Asian Patients with Advanced ALK-positive Non-small Cell Lung Cancer[J].Cancer Res Treat，2018，50（3）：691-700.
[9]	冯雨，崔东，钱如林.PD-1 抑制剂Pembrolizumab 联合培美曲塞治疗非小细胞肺癌的疗效观察[J].医学研究杂志，2019，48（7）：75-80.
[10]	Li MH，Tsai JT，Ting LL，et al.Comparison of Thoracic Radiotherapy Efficacy Between Patients With and Without EGFR-mutated Lung Adenocarcinoma[J].In Vivo，2018，32（1）：203-209.
[11]	张宇祥，郝登荣.培美曲塞联合贝伐珠单抗对非鳞状非小细胞肺癌维持期治疗的有效性分析[J].国际呼吸杂志，2019，39（8）：567-571.
[12]	Kikuchi H，Sakakibara-Konishi J，Furuta M，et al.Numb has distinct function in lung adenocarcinoma and squamous cell carcinoma[J].Oncotarget，2018，9（50）：29 379-29 391.
[13]	杨威，曾琼，张贵芳，等.培美曲塞联合顺铂治疗非鳞型非小细胞肺癌的疗效观察[J].实用癌症杂志，2018，8（1）：66-68.
[14]	Zhang L，Li J，Lv X，et al.MID1-PP2A complex functions as new insights in human lung adenocarcinoma[J].J Cancer Res Clin Oncol，2018，144（5）：855-864.
[15]	李雅芳，王勇.培美曲塞注射剂与多西他赛注射剂治疗非小细胞肺癌患者的临床研究[J].中国临床药理学杂志，2019，35（12）：1227-1229.
[16]	孟娟，王美清，李建旺，等.克唑替尼对比培美曲塞二钠联合顺铂一线治疗ALK 阳性晚期非小细胞肺癌的临床研究[J].国际肿瘤学杂志，2018，45（1）：63-64.
[17]	韩真真，徐小萌，衣晓丽，等.阿帕替尼联合培美曲塞治疗老年晚期非鳞非小细胞肺癌的疗效观察[J].中国肿瘤临床，2019，6（18）：949-952.
[18]	Ding X，Zhang S，Li X，et al.Profiling expression of coding genes，long noncoding RNA，and circular RNA in lung adenocarcinoma by ribosomal RNA-depleted RNA sequencing[J].FEBS Open Bio，2018，8（4）：544-555.